Logo
x

Search category

Subscribe Now

apellis

Apellis Presented P-III (GALE) Extension Study Results of Syfovre for Geographic Atrophy at ASRS 2023

Apellis Presented P-III (GALE) Extension Study Results of Syfovre for Geographic Atrophy at ASRS 2023

  • August 1, 2023
PharmaShots Weekly Snapshots (April 24 - 28, 2023)

PharmaShots Weekly Snapshots (April 24 - 28, 2023)

  • April 28, 2023
Apellis Presents P-III Studies (OAKS) and (DERBY) Results of Syfovre (pegcetacoplan) in Patients with Geographic Atrophy at ARVO 2023

Apellis Presents P-III Studies (OAKS) and (DERBY) Results of Syfovre (pegcetacoplan) in Patients with Geographic Atrophy at ARVO 2...

  • April 24, 2023
Apellis’ Syfovre Receives the US FDA’s Approval as the First Treatment for Geographic Atrophy

Apellis’ Syfovre Receives the US FDA’s Approval as the First Treatment for Geographic Atrophy

  • February 21, 2023
Apellis Presents 24-Month P-III (OAKS) Post Hoc Results of Pegcetacoplan for the Treatment of Geographic Atrophy at AAO 2022

Apellis Presents 24-Month P-III (OAKS) Post Hoc Results of Pegcetacoplan for the Treatment of Geographic Atrophy at AAO 2022

  • October 3, 2022
Apellis Reports P-III (DERBY) and (OAKS) Studies Results of Pegcetacoplan for Geographic Atrophy

Apellis Reports P-III (DERBY) and (OAKS) Studies Results of Pegcetacoplan for Geographic Atrophy

  • August 25, 2022
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.